A possible favorable effect of colchicine in IgA nephropathy in a carrier of a MEFV mutation.
IgA nephropathy is the most common primary glomerulopathy. Currently, no satisfactory treatment is available and as a result, a significant proportion of affected patients progress to end-stage renal disease. We present a patient with IgA nephropathy in whom continuous colchicine treatment induced remission, which has lasted for 22 years. The patient was a carrier of a mutation in the FMF gene (MEFV). This case raises hopes for a better prognosis in at least one subgroup of IgA nephropathy, consisting of patients who happen to be heterozygous carriers of MEFV mutations.
Department of Medicine F, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
L
L
Koukoui
A
A
Blau
J
J
Kopolovic
M
M
Pras
A
A
Livneh
D000328:Adult; D003078:Colchicine / Q000627:therapeutic use*; D010505:Familial Mediterranean Fever / Q000235:genetics*; D005922:Glomerulonephritis, IGA / Q000188:drug therapy* / Q000235:genetics*; D006579:Heterozygote; D006801:Humans; D008297:Male; D009154:Mutation
D003078:Colchicine